# Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
Canonical URL: https://biopharmsignal.com/news/CABA/cabaletta-bio-announces-multiple-upcoming-presentations-including-data-on-rese-cel-without-preconditioning-and-rese-cel-with-automated-manufacturing-at-the-asgct-2026-annual-meeting
Ticker: CABA
Company: Cabaletta Bio
Source: Cabaletta Bio
Published: 2026-04-27 21:00 EST
Original Source URL: https://www.cabalettabio.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-03 11:00 EST — [Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress](https://biopharmsignal.com/news/CABA/cabaletta-bio-announces-new-rese-cel-data-and-development-updates-across-autoimmune-portfolio-including-encouraging-early-pc-free-lupus-findings-at-eular-2026-congress) — Source: Cabaletta Bio
- 2026-05-14 11:05 EST — [Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CABA/cabaletta-bio-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Cabaletta Bio
- 2026-05-14 11:00 EST — [Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting](https://biopharmsignal.com/news/CABA/cabaletta-bio-presents-preconditioning-free-clinical-data-and-automated-manufacturing-translational-data-for-rese-cel-at-asgct-2026-annual-meeting) — Source: Cabaletta Bio
- 2026-05-04 10:35 EST — [Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering](https://biopharmsignal.com/news/CABA/cabaletta-bio-announces-pricing-of-150-million-underwritten-offering) — Source: Cabaletta Bio
- 2026-04-28 12:00 EST — [Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel](https://biopharmsignal.com/news/CABA/cabaletta-bio-and-cellares-announce-10-year-commercial-supply-agreement-for-rese-cel) — Source: Cabaletta Bio
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)